Insights

Gathering insights about Medici…

Similar companies to Medici

Medici Tech Stack

Medici uses 8 technology products and services including Squarespace, Cloudflare, MySQL, and more. Explore Medici's tech stack below.

Squarespace
Content Management System
Cloudflare
Content Management System
MySQL
Database
Shopify
E-commerce
jQuery
Javascript Libraries
WPBakery
Page Builders
Vimeo
Video Players
Bokeh
Visualisation Software

Media & News

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
LA JOLLA, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced enrollment of the first patient in the NIH-funded Expanded Access Program (EAP) trial to evaluate MN-166 (ibudilast) in patients with Amyotrophic Lateral Sclerosis (ALS).
Apr 08, 2025 | www.globenewswire.com
MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announces the study update and interim analysis results from the Company's COMBAT-ALS Phase 2b/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) will be presented at the 35th International Symposium on ALS/MND held December 6-8, 2024 in Montreal, Canada.
Dec 05, 2024 | www.globenewswire.com
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
LA JOLLA, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), announces that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a pending patent application for MN-001 (Tipelukast) to cover "Method to Decrease Triglyceride Synthesis in a Liver of a Subject." The allowed claims cover a groundbreaking method for decreasing triglyceride synthesis in the liver by administering MN-001 (Tipelukast) or its metabolite or pharmaceutically acceptable salt. This method is particularly beneficial for subjects diagnosed with insulin resistance, pre-diabetes, or diabetes. Once issued, this patent is expected to expire no earlier than May 26, 2042.
Nov 14, 2024 | www.globenewswire.com
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
LA JOLLA, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it was notified by Sanofi that the Sanofi/Novartis litigation was settled. Accordingly, MediciNova is entitled to receive a certain amount of monetary damages through this settlement. Further details will be provided as they become available.
Nov 11, 2024 | www.globenewswire.com
MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)
LA JOLLA, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the lead Principal Investigator of this clinical trial, Björn Oskarsson, MD, FAAN presented the update of an ongoing Phase 2/3 clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) patients at the 2024 Annual NEALS Meeting being held virtually on Oct 21-24, 2024.
Oct 23, 2024 | www.globenewswire.com
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
LA JOLLA, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the National Institutes of Health (NIH) - Neurological Disorders and Stroke (NINDS) has awarded $22 million for an intermediate size Expanded Access Protocol (EAP) to evaluate the efficacy of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)1,2.
Sep 30, 2024 | www.globenewswire.com
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
LA JOLLA, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding a clinical trial of MN-166 (ibudilast) in the treatment of Amyotrophic Lateral Sclerosis (ALS), COMBAT-ALS study has been selected for a poster presentation at the 35th International Symposium on ALS / MND to be held December 6-8, 2024 in Montreal, Canada. The poster presentation will be presented by lead Principal Investigator of this clinical trial, Björn Oskarsson, MD, FAAN Associate Professor of Neurology at Jacksonville, FL, Director of ALS, Center of Excellence.
Sep 09, 2024 | www.globenewswire.com

Medici's Email Address Formats

Medici uses at least 2 format(s):

Medici Email Formats	Example	Percentage
First.Last@medici.md	John.Doe@medici.md	61%
First@medici.md	John@medici.md	26%
Last@medici.md	Doe@medici.md	10%
FirstLast@medici.md	JohnDoe@medici.md	3%

Frequently Asked Questions

Where is Medici's headquarters located?

Medici's main headquarters is located at 7500 Rialto Blvd Austin, Texas 78735 US. The company has employees across 6 continents, including North AmericaAsiaEurope.

What is Medici's stock symbol?

Medici is a publicly traded company; the company's stock symbol is MNOV.

What is Medici's official website and social media links?

Medici's official website is medi.ci and has social profiles on LinkedIn.

How much revenue does Medici generate?

As of April 2025, Medici's annual revenue reached $75M.

What is Medici's NAICS code?

Medici's NAICS code is 62 - Health Care and Social Assistance.

How many employees does Medici have currently?

As of April 2025, Medici has approximately 265 employees across 6 continents, including North AmericaAsiaEurope. Key team members include Chief Executive Officer And President: S. D.Chief Financial Officer: B. T.Chief Technology Officer: D. P.. Explore Medici's employee directory with LeadIQ.

What industry does Medici belong to?

Medici operates in the Hospitals and Health Care industry.

What technology does Medici use?

Medici's tech stack includes SquarespaceCloudflareMySQLShopifyjQueryWPBakeryVimeoBokeh.

What is Medici's email format?

Medici's email format typically follows the pattern of . Find more Medici email formats with LeadIQ.

When was Medici founded?

Medici was founded in 2016.

Medici

Hospitals and Health CareTexas, United States201-500 Employees

Medici is a virtual health care system that gives enrolled stakeholders and dependents access to a personal medical team made up of exceptional doctors, nurses, and specialists. Medici seamlessly integrates primary care, sick care, navigation, pediatric advice, counseling, condition management, medications, lab work, imaging, and even veterinary advice into one system, accessible from your phone.

Company Overview

Headquarters: 7500 Rialto Blvd Austin, Texas 78735 US
Website: medi.ci
Stock Symbol: MNOV
NAICS Code: 62 - Health Care and Social Assistance
Founded: 2016
Employees: 201-500

Media & News

Funding & Financials

$50M$100M
Medici's revenue is in the range of $50M$100M

Funding & Financials

$50M$100M
Medici's revenue is in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Medici

Amwell

Heal

Roman

Doctor On Demand

SteadyMD

HealthTap

CirrusMD

GoodRx

First Stop Health

Maven Clinic

PlushCare

Medici Tech Stack

Media & News

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

Medici's Email Address Formats

Frequently Asked Questions

Where is Medici's headquarters located?

What is Medici's stock symbol?

What is Medici's official website and social media links?

How much revenue does Medici generate?

What is Medici's NAICS code?

How many employees does Medici have currently?

What industry does Medici belong to?

What technology does Medici use?

What is Medici's email format?

When was Medici founded?

Medici

Company Overview

Media & News

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?